Below are the most recent publications written about "Positron-Emission Tomography" by people in Profiles.
-
Petersen KK, Mil?-Alom? M, Li Y, Du L, Xiong C, Tosun D, Saef B, Saad ZS, Du-Cuny L, Coomaraswamy J, Mordashova Y, Rubel CE, Meyers EA, Shaw LM, Dage JL, Ashton NJ, Zetterberg H, Ferber K, Triana-Baltzer G, Baratta M, Rosenbaugh EG, Cruchaga C, McDade E, Holtzman DM, Morris JC, Sabandal JM, Bateman RJ, Bannon AW, Potter WZ, Schindler SE. Predicting onset of symptomatic Alzheimer's disease with plasma p-tau217 clocks. Nat Med. 2026 Mar; 32(3):1085-1094.
-
C?novas R, Cox T, Dor? V, Bourgeat P, Fripp J, Feizpour A, Shishegar R, Fowler CJ, Laws SM, Porter T, Rainey-Smith S, Shaw LM, Bateman RJ, Li Y, Vitaliy O, Weiner MW, Morris JC, Benzinger TLS, Schindler SE, Nakamura A, Iwatsubo T, Ikeuchi T, Kato T, Maruff P, Sohrabi HR, Rowe CC, Martins RN, Masters CL, Doecke JD. When Does Alzheimer's Disease Start? Plasma A?42/40 Assays Show Steep Changes at A?-PET Centiloid 15, Mean Age of 66?Years. Ann Neurol. 2026 May; 99(5):1327-1342.
-
Basile GA, Ielo A, Bonanno L, Cerasa A, Santoro G, Milardi D, Anastasi GP, Torre A, Baldari S, Laudicella R, Gaeta M, Quartu M, Serra MP, Trucas M, Quartarone A, Saranathan M, Cacciola A. Shared functional organization between pulvinar-cortical and cortico-cortical connectivity and its structural and molecular imaging correlates. Elife. 2025 Oct 13; 13.
-
Cousins KAQ, Korecka M, Wan Y, Vulaj A, Brown C, Tropea TF, Lee EB, Tosun D, Landau SM, Okonkwo OC, Mindt MR, Weiner MW, Irwin DJ, Wolk DA, Shaw LM. Comparison of plasma p-tau217/A?42, p-tau217, and A?42/A?40 biomarkers by race to detect Alzheimer's disease. Alzheimers Dement. 2025 Aug; 21(8):e70469.
-
Azimi MS, Felfelian V, Zeraatkar N, Dadgar H, Arabi H, Zaidi H. Deep supervised transformer-based noise-aware network for low-dose PET denoising across varying count levels. Comput Biol Med. 2025 Sep; 196(Pt A):110733.
-
Bu XL, Zhu W, Wang QH, Liu ZT, Bao YY, Bai YD, Li JH, Liu ZH, Zhao JL, Xiang Y, Jin WS, Wang J, Lei X, Wang YJ. Association between self-reported multimorbidity and longitudinal brain A? deposition in Alzheimer's disease. Nat Commun. 2025 Jul 01; 16(1):5905.
-
Mil?-Alom? M, Tosun D, Schindler SE, Hausle I, Petersen KK, Li Y, Dage JL, Du-Cuny L, Saad ZS, Saef B, Triana-Baltzer G, Raunig DL, Coomaraswamy J, Baratta M, Meyers EA, Mordashova Y, Rubel CE, Ferber K, Kolb H, Ashton NJ, Zetterberg H, Rosenbaugh EG, Sabandal M, Shaw LM, Bannon AW, Potter WZ. Timing of Changes in Alzheimer's Disease Plasma Biomarkers as Assessed by Amyloid and Tau PET Clocks. Ann Neurol. 2025 Sep; 98(3):508-523.
-
Duong MT, Das SR, Khandelwal P, Lyu X, Xie L, McGrew E, Dehghani N, McMillan CT, Lee EB, Shaw LM, Yushkevich PA, Wolk DA, Nasrallah IM. Hypometabolic mismatch with atrophy and tau pathology in mixed Alzheimer's and Lewy body disease. Brain. 2025 May 13; 148(5):1577-1587.
-
Ding H, Lyu C, Karjadi C, Sunderaraman P, Young CB, Mormino EC, Low S, Devine S, Gifford K, Au R, Lin H. Association of the digital clock drawing test with amyloid and tau PET biomarkers in low age risk adults. Sci Rep. 2025 Apr 01; 15(1):11104.
-
Leuzy A, Bollack A, Pellegrino D, Teunissen CE, La Joie R, Rabinovici GD, Franzmeier N, Johnson K, Barkhof F, Shaw LM, Arkhipenko A, Schindler SE, Honig LS, Moscoso Rial A, Sch?ll M, Zetterberg H, Blennow K, Hansson O, Farrar G. Considerations in the clinical use of amyloid PET and CSF biomarkers for Alzheimer's disease. Alzheimers Dement. 2025 Mar; 21(3):e14528.